Anavex Life Sciences Corp (AVXL)

[B60611]

All the optimism is based on liraglutide (Saxenda) slowing cognitive decline in mild ALZ by 18% after a year. Hopefully Novo/Rybelsus can replace the Mabs as complementary treatments to Blarcamesine, but color me not concerned as it relates to an AVXL investment, especially when we can offer a sizable portion of the ALZ population an 84% slowing of cognitive decline. Rybelsus is very unlikely to be approved for ALZ before 2027. Moreover, I sincerely doubt doctors start prescribing it off-label as it’ll cost patients about $12,000/yr. And the oral version at 14mg, as in the soon to readout trial, has very low absorption and is marginally less effective (for weight loss) than injection form, Saxenda. Finally, Rybelsus causes significant side effects (40% nausea) which will eliminate a lot of fragile older folks. Not to mention, many of them can’t afford to lose weight.

The repeated scaremongering on this board about the Rybelsus trial is ludicrous, to the point where it seems other motivations are at play.